Olema Pharmaceuticals (OLMA) EBIT (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly EBIT of -$58.0 million for Q1 2026, down 66.28% year-over-year from -$172.0 million in Q1 2025, and down 15.78% quarter-over-quarter from -$50.1 million in Q4 2025.
Olema Pharmaceuticals (OLMA) EBIT (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported EBIT for 7 consecutive years, with -$58.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 66.28% year-over-year to -$58.0 million; the TTM figure through Mar 2026 stood at -$201.8 million (down 41.33% YoY), while the FY2025 annual figure was -$178.7 million, down 25.62% from the prior year.
- EBIT declined to -$58.0 million in Q1 2026 per OLMA's latest filing, from -$50.1 million in the prior quarter.
- Across five years, EBIT topped out at -$21.6 million in Q2 2023 and bottomed at -$58.0 million in Q1 2026.
- Historically, EBIT has averaged -$34.8 million across 5 years, with a median of -$33.5 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT sank 101.51% — and 2023, when it jumped 35.12%.
- Olema Pharmaceuticals' EBIT stood at -$27.2 million in 2022, then slipped by 11.75% to -$30.4 million in 2023, then retreated by 20.88% to -$36.8 million in 2024, then tumbled by 36.22% to -$50.1 million in 2025, then declined by 15.78% to -$58.0 million in 2026.
- Business Quant data shows OLMA's EBIT at -$58.0 million in Q1 2026, -$50.1 million in Q4 2025, and -$45.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | -67.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.18 Mn |
| Mar 31, 2026 | -57.99 Mn |
| Dec 31, 2025 | -50.08 Mn |
| Sep 30, 2025 | -45.88 Mn |
| Jun 30, 2025 | -47.86 Mn |
| Mar 31, 2025 | -34.87 Mn |
| Dec 31, 2024 | -36.77 Mn |
| Sep 30, 2024 | -37.62 Mn |
| Jun 30, 2024 | -33.53 Mn |
| Mar 31, 2024 | -34.34 Mn |
| Dec 31, 2023 | -30.42 Mn |
| Sep 30, 2023 | -23.34 Mn |
| Jun 30, 2023 | -21.60 Mn |
| Mar 31, 2023 | -29.60 Mn |
| Dec 31, 2022 | -27.22 Mn |
| Sep 30, 2022 | -23.22 Mn |
| Jun 30, 2022 | -33.29 Mn |
| Mar 31, 2022 | -23.25 Mn |
| Dec 31, 2021 | -21.76 Mn |
| Sep 30, 2021 | -17.76 Mn |